Correction to: Durvalumab: A Review in Advanced Biliary Tract Cancer

被引：0
|
作者：
Simon Fung
Yahiya Y. Syed
机构：
[1] Springer Nature,
来源：
Targeted Oncology | 2024年 / 19卷 / 1期
关键词：
D O I：
10.1007/s11523-023-01021-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：129 / 129
相关论文
共 50 条
  • [41] Efficacy of gemcitabine in advanced unresectable biliary tract cancer
    Mehrotra, B
    Ahmed, S
    Bhargava, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 377S - 377S
  • [42] New Treatment Options for Advanced Biliary Tract Cancer
    Mizrahi, Jonathan D.
    Shroff, Rachna T.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)
  • [43] Current systemic treatment for advanced biliary tract cancer
    Vogel, Arndt
    Saborowski, Anna
    ONKOLOGE, 2022, 28 (04): : 287 - 298
  • [44] Analysis of 94 patients with advanced biliary tract cancer
    Andritzky, B.
    Adler, S.
    Burkholder, I.
    Thoem, I.
    Schuch, G.
    Goern, M.
    Schilling, G.
    Edler, L.
    Bokemeyer, C.
    Laack, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Advanced Squamous Cell Carcinoma of Gall Bladder Masquerading as Liver Abscess With Review of Literature Review on Advanced Biliary Tract Cancer
    Bin Waqar, Syed Hamza
    Salahi, Navid
    Li Zhonghua
    McFarlane, Isabel M.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (08)
  • [46] FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer
    Casak, Sandra J.
    Kumar, Vaibhav
    Song, Chi
    Yuan, Mengdie
    Amatya, Anup K.
    Cheng, Joyce
    Mishra-Kalyani, Pallavi S.
    Tang, Shenghui
    Lemery, Steven J.
    Auth, Doris
    Davis, Gina
    Kluetz, Paul G.
    Pazdur, Richard
    Fashoyin-Aje, Lola A.
    CLINICAL CANCER RESEARCH, 2024, 30 (16) : 3371 - 3377
  • [47] Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (04) : 343 - 350
  • [48] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, F.
    Bouattour, M.
    Valle, J. W.
    Vogel, A.
    Kim, J. W.
    Kitano, M.
    Chen, J. -S.
    Burris, H.
    Zaucha, R.
    Qin, S.
    Evesque, L.
    Zhen, D. B.
    Gupta, V. G.
    Park, J. O.
    Zotkiewicz, M.
    Rokutanda, N.
    Cohen, G.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 127 - 128
  • [49] Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer
    Doki, Yuichiro
    Ueno, Makoto
    Hsu, Chih-Hung
    Oh, Do-Youn
    Park, Keunchil
    Yamamoto, Noboru
    Ioka, Tatsuya
    Hara, Hiroki
    Hayama, Manabu
    Nii, Masahiro
    Komuro, Keiko
    Sugimoto, Mariko
    Tahara, Makoto
    CANCER MEDICINE, 2022, 11 (13): : 2550 - 2560
  • [50] Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma
    Monge, Cecilia
    Xie, Changqing
    Myojin, Yuta
    Coffman-D'Annibale, Kelley L.
    Hrones, Donna
    Brar, Gagandeep
    Wang, Sophie
    Budhu, Anuradha
    Figg, William D.
    Cam, Maggie
    Finney, Richard
    Levy, Elliot B.
    Kleiner, David E.
    Steinberg, Seth M.
    Wang, Xin Wei
    Redd, Bernadette
    Wood, Bradford J.
    Greten, Tim F.
    CANCER MEDICINE, 2024, 13 (03):
12345